Anti-CD19 CAR-T cell therapy (iCarTAB BioMed)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameAnti-CD19 CAR-T cell therapy (iCarTAB BioMed)
Drug Alias NameAnti-CD19-CAR-T cells抗CD19-CAR-T细胞疗法（爱康得生物）anti-CD19 CAR T cells (爱康得)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryVietnamMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAikangd Biomedical Technology (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVinmec Research Institute Of Stem Cell And Gene TechnologyAikangd Biomedical Technology (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A